https://www.selleckchem.com/products/fht-1015.html
9%), and approximately two-thirds of patients used MMI for 3 months prior to RAI therapy. Use of ATD prior to RAI therapy (P = .003) and higher 6-hour I-123 thyroid uptake prior to I-131 RAI therapy (P.001) were associated with treatment failure. MMI use 3 months was also associated with treatment failure (P = .002). More patients may be presenting for RAI therapy after failing first-line ATD therapy. MMI use 3 months was associated with RAI treatment failure. Further studies are needed to investigate the association be